AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models - PubMed (original) (raw)
AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models
Barry R Davies et al. Mol Cancer Ther. 2007 Aug.
Abstract
Constitutive activation of the extracellular signal-regulated kinase 1/2 (ERK1/2) mitogen-activated protein kinase (MAPK) signaling pathway in human cancers is often associated with mutational activation of BRAF or RAS. MAPK/ERK kinase 1/2 kinases lie downstream of RAS and BRAF and are the only acknowledged activators of ERK1/2, making them attractive targets for therapeutic intervention. AZD6244 (ARRY-142886) is a potent, selective, and ATP-uncompetitive inhibitor of MAPK/ERK kinase 1/2. In vitro cell viability inhibition screening of a tumor cell line panel found that lines harboring BRAF or RAS mutations were more likely to be sensitive to AZD6244. The in vivo mechanisms by which AZD6244 inhibits tumor growth were investigated. Chronic dosing with 25 mg/kg AZD6244 bd resulted in suppression of growth of Colo-205, Calu-6, and SW-620 xenografts, whereas an acute dose resulted in significant inhibition of ERK1/2 phosphorylation. Increased cleaved caspase-3, a marker of apoptosis, was detected in Colo-205 and Calu-6 but not in SW-620 tumors where a significant decrease in cell proliferation was detected. Chronic dosing of AZD6244 induced a morphologic change in SW-620 tumors to a more differentiated phenotype. The potential of AZD6244 in combination with cytotoxic drugs was evaluated in mice bearing SW-620 xenografts. Treatment with tolerated doses of AZD6244 and either irinotecan or docetaxel resulted in significantly enhanced antitumor efficacy relative to that of either agent alone. These results indicate that AZD6244 has potential to inhibit proliferation and induce apoptosis and differentiation, but the response varies between different xenografts. Moreover, enhanced antitumor efficacy can be obtained by combining AZD6244 with the cytotoxic drugs irinotecan or docetaxel.
Similar articles
- In vitro and in vivo radiosensitization with AZD6244 (ARRY-142886), an inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 kinase.
Chung EJ, Brown AP, Asano H, Mandler M, Burgan WE, Carter D, Camphausen K, Citrin D. Chung EJ, et al. Clin Cancer Res. 2009 May 1;15(9):3050-7. doi: 10.1158/1078-0432.CCR-08-2954. Epub 2009 Apr 14. Clin Cancer Res. 2009. PMID: 19366835 Free PMC article. - The mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) enhances the radiation responsiveness of lung and colorectal tumor xenografts.
Shannon AM, Telfer BA, Smith PD, Babur M, Logie A, Wilkinson RW, Debray C, Stratford IJ, Williams KJ, Wedge SR. Shannon AM, et al. Clin Cancer Res. 2009 Nov 1;15(21):6619-29. doi: 10.1158/1078-0432.CCR-08-2958. Epub 2009 Oct 20. Clin Cancer Res. 2009. PMID: 19843666 - Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines.
Balmanno K, Chell SD, Gillings AS, Hayat S, Cook SJ. Balmanno K, et al. Int J Cancer. 2009 Nov 15;125(10):2332-41. doi: 10.1002/ijc.24604. Int J Cancer. 2009. PMID: 19637312 - Development of ERK1/2 inhibitors as a therapeutic strategy for tumour with MAPK upstream target mutations.
Miao L, Tian H. Miao L, et al. J Drug Target. 2020 Feb;28(2):154-165. doi: 10.1080/1061186X.2019.1648477. Epub 2019 Aug 13. J Drug Target. 2020. PMID: 31340679 Review. - Selumetinib: a selective MEK1 inhibitor for solid tumor treatment.
Hedayat M, Jafari R, Majidi Zolbanin N. Hedayat M, et al. Clin Exp Med. 2023 Jun;23(2):229-244. doi: 10.1007/s10238-021-00783-z. Epub 2022 Feb 16. Clin Exp Med. 2023. PMID: 35171389 Review.
Cited by
- Preclinical characterization of tunlametinib, a novel, potent, and selective MEK inhibitor.
Liu Y, Cheng Y, Huang G, Xia X, Wang X, Tian H. Liu Y, et al. Front Pharmacol. 2023 Sep 21;14:1271268. doi: 10.3389/fphar.2023.1271268. eCollection 2023. Front Pharmacol. 2023. PMID: 37808191 Free PMC article. - Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas.
Armstrong AE, Belzberg AJ, Crawford JR, Hirbe AC, Wang ZJ. Armstrong AE, et al. BMC Cancer. 2023 Jun 16;23(1):553. doi: 10.1186/s12885-023-10996-y. BMC Cancer. 2023. PMID: 37328781 Free PMC article. Review. - Benzimidazole and its derivatives as cancer therapeutics: The potential role from traditional to precision medicine.
Lee YT, Tan YJ, Oon CE. Lee YT, et al. Acta Pharm Sin B. 2023 Feb;13(2):478-497. doi: 10.1016/j.apsb.2022.09.010. Epub 2022 Sep 21. Acta Pharm Sin B. 2023. PMID: 36873180 Free PMC article. Review. - Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors.
Malone CF, Kim M, Alexe G, Engel K, Forman AB, Robichaud A, Conway AS, Goodale A, Meyer A, Khalid D, Thayakumar A, Hatcher JM, Gray NS, Piccioni F, Stegmaier K. Malone CF, et al. Cancer Res. 2023 Jan 18;83(2):285-300. doi: 10.1158/0008-5472.CAN-21-4309. Cancer Res. 2023. PMID: 36398965 Free PMC article. - Escape from G1 arrest during acute MEK inhibition drives the acquisition of drug resistance.
Channathodiyil P, May K, Segonds-Pichon A, Smith PD, Cook SJ, Houseley J. Channathodiyil P, et al. NAR Cancer. 2022 Oct 17;4(4):zcac032. doi: 10.1093/narcan/zcac032. eCollection 2022 Dec. NAR Cancer. 2022. PMID: 36267209 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous